KPV

A tripeptide (Lys-Pro-Val) based on o-Melanocyte stimulating hormone (o-MSH) molecule.
KPV possesses 68 anti-inflammatory properties, although its mechanisms are still largely unmapped. o-MSH is an endogenous tridecapeptide cleavage product of proopiomelanocortin that has protective and anti-inflammatory effects.
The anti-inflammatory activity of u-MSH is reported facilitated by three N-terminal amino acids, lysine-proline-valine, known as KPV.

KPV peptide was reported to exert a more potent anti-inflammatory effect than o-MSH itself.
A study also reported that KPV can attenuate the inflammatory responses of colonic epithelial and immune cells and reduce the incidence of colitis in vivo upon oral administration. In glial cells KPV led to markedly decreased expression of TNF- o mRNA and reduced release of NO after stimulation with beta-amyloid or interferon-gamma.

• Anti-inflammatory – Metaflammation.
• GUT tissue support
• Immune modulation

• General Dosage:  500mcg
• Can be used synergistically with BPC-157 500mcg orally for improved GUT healing

The ability of KPV to be administered by various methods is also appealing over alpha-MsH, which is only injection. KPV can be used orally, transdermally, or injection without side effects.

KPV peptide administered orally is reported safe and efficacious in recommended dosages.
KPV is not reported to cause skin pigmentation, unlike alpha-MSH.